Prescribed Medication:

1. Vortioxetine 10 mg 1 tab OD
2. Abilify 2.5 mg ½ tab OD

DRUG STUDY
DRUG MECHANISM OF INDICATION CONTRAINDICATION ADVERSE NURSING
NAME ACTION EFFECTS RESPONSIBILITIES
Vortioxetine Antidepressant effect It is indicated  Contraindicated in CNS: - Monitor patient for
10 mg of vortioxetine isn’t for the patients dizziness, signs and symptoms
1 tab OD fully understood, but is treatment of hypersensitive to abnormal of worsening
thought to be related major drug or its dreams. depression,
to its enhancement of depressive component. emergence of
serotonergic activity in disorder  Use of MAO GI: nausea, suicidal ideation and
the CNS through (MDD). inhibitors to treat diarrhea, dry behaviour, or unusual
inhibition of the psychiatric mouth, changes in
reuptake of serotonin disorders with constipation, behaviour, especially
(5-HT), as well as 5- vortioxetine is vomiting, during initial
HT3 receptor contraindicated flatulence. treatment or with
antagonism and 5- because of an dosage changes,
HT1A receptor increased risk of GU: sexual either increases or
antagonism. serotonin dysfunction. decreases.
syndrome. - Screen patient for
SKIN: bipolar disorder
pruritus. before drug initiation.
Drug isn’t approved
for use in bipolar
depression.
- Monitor patient for
signs and symptoms
 of hyponatremia and
SIADH. Discontinue
drug in hyponatremia
occurs.
- Monitor patient for
signs and symptoms
of serotonin
syndrome, including
mental status
changes, autonomic
instability,
neuromuscular
symptoms, seizures,
or severe GI
symptom.
Discontinue drug
immediately if signs
and symptoms occur.
- Tell patient to report
all adverse reactions
to prescriber.
- Warn patient not to
stop abruptly or
without discussing
with prescriber.
- Caution patient about
operating machinery
or doing tasks that
require alertness
while taking drug.
DRUG MECHANISM INDICATION CONTRAINDICATION ADVERSE EFFECTS NURSING
NAME OF ACTION RESPONSIBILITIES
Abilify Thought to exert It is indicated  Contraindicated Body as a Whole: - Monitor diabetics for
partial agonist for adjunctive in patients Headache, asthenia, loss of glycemic control.
2.5 activity at treatment of hypersensitive to fever, flu-like symptoms,
mg dopamine 2 and Major drug. peripheral edema, chest - Monitor cardiovascular
½ tab 5-HT1A depressive  Drug isn’t pain, neck pain, neck status. Assess for and
OD receptors and disorder approved for use rigidity. report orthostatic
antagonist (MDD). in children with hypotension. Take BP
activity at 5- depression. CNS: Anxiety, insomnia, supine then in sitting
HT2A receptors. light-headedness, position. Report systolic
somnolence, akathisia, drop of >15–20 mm Hg.
tremor, extrapyramidal Patients at increased
symptoms, depression, risk are those who are
nervousness, increased dehydrated,
salivation, hostility, hypovolemic, or
suicidal thought, manic receiving concurrent
reaction, abnormal gait, antihypertensive
confusion, cogwheel therapy.
rigidity.

CV: Hypertension, - Monitor body

tachycardia,
hypotension,
bradycardia. Risk of
stroke in elderly with
dementia-related
psychosis.
GI: Nausea, vomiting,
constipation, anorexia.
temperature in
situations likely to
elevate core
temperature (e.g.,
exercising strenuously,
exposure to extreme
heat, receiving drugs
with anticholinergic
activity, or being subject

Hematologic:
Ecchymosis, anemia. - Monitor for and report
Metabolic: Weight gain,
weight loss,
hyperglycemia, diabetes
mellitus, increased - Monitor for and
creatine kinase.
Musculoskeletal:
Muscle cramp.
Respiratory: Rhinitis,
cough.
Skin: Rash. Special
Senses: Blurred vision.
to dehydration).
signs of tardive
dyskinesia.
immediately report S&S
of neuroleptic malignant
syndrome (NMS) that
include: hyperpyrexia,
muscle rigidity, altered
mental status, irregular
pulse or blood pressure,
tachycardia,
diaphoresis, and
cardiac dysrhythmia.
Withhold drug if NMS is
suspected.

- Lab tests: Monitor

periodically Hct & Hgb.
Monitor periodically
blood glucose. Monitor
for elevated CPK and
myoglobinuria if NMS is
suspected.